☀️The Breast Cancer Session featuring #AntibodyDrugConjugates stole the morning show at the scientific conference Sarah Cannon Docs #SCRI ⭐️Drs. Erika Hamilton, MD, Joyce O'Shaughnessy, Denise Yardley led an impactful discussion on ADC drug development, with a spotlight on

Giving a breast oncologist perspective on this debate. 1) Estrogen-only HRT is not linked to a higher risk of breast cancer (BC) in pts with no BC history. Cite: Women’s Health Initiative 2) HRT DID increase risk of recurrence in BC survivors. Cite HABITS trial.

The NATALEE phase 3 trial of adjuvant ribo for stage II-III HR+ BC is published in NEJM. With 28 months f-up, adding ribo for 3y to adjuvant AI led to a significant benefit in 3y iDFS (Δ≃3%). Updated results at SABCS23 were consistent with this analysis. nejm.org/doi/full/10.10…

Exciting that a new option is on the horizon. Magnitude of benefit, patient reported outcomes, adverse-events, and understanding the role (if any) of HER2-low as a biomarker will shape the place T-DXd ultimately takes for HR+ HER2-low or ultralow MBC in the lineup. #DB06 #bcsm

Agree! Really looking forward to it! Such an important cause!

Some fun #Summerlark24 selfies with Katherine Ansley, MD #BethFisher #KatieDuckworth at Barenaked Ladies concert supporting Atrium Health Wake Forest Baptist Wake Forest Baptist - Comprehensive Cancer Center Patient Support Program Levine Cancer Atrium Health

The best night of the year at #summerlark raising funds and awareness for our cancer patient support program! Thank you Barenaked Ladies for an amazing show!

#datoDXd vs. chemo in TROPIONBr01 Overall G3 AE half that of chemo w/ dato 🗣️ stomatitis, ~50%, onset ~ 3 wks. Still ? what % got steroid prophylaxis 👀 ocular events, ~40%, most G1 Nausea 🤢 & alopecia ⬆️ w/ dato, neuropathy 🖐️ ⬇️ compared w/ chemo #ESMOBreast24 ESMO - Eur. Oncology

Inavolisib plus fulvestrant with palbociclib was granted breakthrough therapy designation by the US FDA for PIK3CA mutant tumors with ERv+ MBC who have recurred on or within 12 months of ET. gene.com/media/press-re…

Long awaited post monarch. Abema post mostly palbo improved PFS with small median but sign HR. Impact prob less in visceral Mets. In ET sensitive without targ mut and with non visceral disease a new option. #ASCO24 OncoAlert Kevin Kalinsky, MD, MS

Great review by ⁦Ruth O'Regan⁩ on ET in MBC. Inavo in ET resistance shows benefit; no role for chemo in 1st line setting; sequencing cdks can produce benefit but based on other available options may have to be selective in its use. #asco24

Beautiful presentation by Antonio Giordano, MD PhD #ASCO24 on enfortumab vedotin in HR+ and TN MBC. Response rates and PFS below, independent of nectin expression. Unclear what the strategy of sequencing would be with this agent, although clearly has efficacy. OncoAlert

In 1st line HER2+ MBC, THP=eribulinHP. A good nugget to know for pts who cannot tolerate taxane therapy @asco ⁦OncoAlert⁩

The most awaited #BreastCancer data presented at #ASCO24 by G Curigliano MD PhD (AIOM board & ESMO - Eur. Oncology council member): #TDXd significantly improves PFS and ORR as first chemotherapy line in HR+/HER2- disease progressing on ET with very interesting signal in HER2ultralow OncoAlert

Great discussion by dr Krop Yale University: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24 OncoAlert

#ASCO24 Rebecca Shatsky, MD fabulous presentation of I-SPY 2 block A neoadjuvant Dato/Durva in MMP hi risk HR+ and TNBC. Hi pCR with just 4 cycles of Rx graduating in the immune + subtype. Data from addl Rx later this year! OncoAlert

AMH appears to be the most meaningful biomarker to define the premenopausal population in RxPonder who can safely omit chemotherapy. #ASCO24 Kevin Kalinsky, MD, MS SWOG Cancer Research Network

DESTINY breast 12 Nancy Lin, MD #ESMO24 ▪️ 12 month PFS overall, similiar w stable and active brain mets 62.9% & 59.6% ▪️ median PFS = 17.3 mon ▪️CNS ORR = 71.7% ▪️12-month OS was maintained in patients with BMs (90.3%) and without BMs (90.6%)

“In my opinion, after today, regardless of brain mets, the standard second line therapy should be T-DXd” says Cristina Saura of the ESMO - Eur. Oncology Guidelines as she discusses DESTINY-Breast12 #ESMO24

#CAPItello290 is negative👎- paclitaxel +/- capiva in 1L #TNBC Heather McArthur, MD, MPH 📍OS 🟰 in all comers & pts w/ PIK3/AKT/PTEN mut (30% of pts) w/ and w/o capi 📌PFS numerically ⬆️ in altered pop 5.6 vs. 7.5 mo Not without toxicity either 💩 #ESMO24 #ESMOAmbassadors #bcsm